RecruitingPhase 4NCT05858645
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Sponsor
University of California, San Francisco
Enrollment
25 participants
Start Date
Oct 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- years of age or older
- Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
Exclusion Criteria7
- taking systemic immunosuppressives in the last 12 weeks
- pregnancy
- severe immunodeficiency (either from genetic or infectious causes).
- tuberculosis or other active serious infection
- active systemic malignancy.
- breast-feeding
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGdeucravacitinib
Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05858645
Related Trials
Proactive TDM Versus Standard Use of Biologics in Psoriasis
NCT0639810615 locations
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
NCT074261201 location
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
NCT073208721 location
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis
NCT049502181 location
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
NCT040806357 locations